Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
88.01 USD | -0.68% | +1.80% | +15.42% |
Apr. 25 | Edwards Lifesciences Q1 Adjusted Earnings, Net Sales Increase, Q2 Guidance Set | MT |
Apr. 25 | Earnings Flash (EW) EDWARDS LIFESCIENCES CORPORATION Posts Q1 EPS $0.66, vs. Street Est of $0.64 | MT |
Evolution of the average Target Price on Edwards Lifesciences Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Edwards Lifesciences Corporation
Baird | |
Leerink Partners | |
Zacks Investment Research | |
Truist Securities | |
RBC Capital Markets | |
Mizuho Securities | |
Citigroup | |
Morgan Stanley | |
Oppenheimer | |
BofA Securities | |
UBS | |
Canaccord Genuity | |
Stifel Nicolaus | |
Jefferies & Co. | |
JPMorgan Chase | |
Wells Fargo Securities | |
Evercore ISI | |
Wolfe Research | |
Deutsche Bank Securities | |
TD Cowen | |
Piper Sandler | |
Barclays | |
Bernstein | |
Raymond James | |
Goldman Sachs | |
Cowen | |
SVB Leerink | |
Credit Suisse | |
Atlantic Equities |
EPS Revisions
- Stock Market
- Equities
- EW Stock
- Consensus Edwards Lifesciences Corporation